Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group.
Sera from remitting and secondary progressive multiple sclerosis patients disrupt the blood-brain barrier.
Development of the Brief Inventory of Perceived Stress.
Arzerra receives approval in Japan
First use of alemtuzumab in Balo's concentric sclerosis: a case report.
The risk of varicella zoster virus infection in multiple sclerosis patients treated with fingolimod.
A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.
Cerebrospinal fluid parameters of B cell-related activity in patients with active disease during natalizumab therapy.
Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey.
Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)
The immune modulator FTY720 targets sphingosine 1-phosphate receptors.
Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis.
Evaluation of an electronic diary for improvement of adherence to interferon beta-1b in patients with multiple sclerosis: design and baseline results of an observational cohort study.
Pilates based core stability training in ambulant individuals with multiple sclerosis: Protocol for a multi-centre randomised controlled trial.
Cross-cultural Adaptation, Reliability, and Validity of the BICAMS in Brazil.
Prevention and treatment of MS: studying the effects of vitamin D.
Generation and Characterization of Fully Human Monoclonal Antibodies Against Human Orai1 for Autoimmune Disease.
Co-enzyme Q10 and idebenone use in Friedreich's ataxia.
Ono to enter license agreements with Merck KGaA
Cluster-tic syndrome as the initial manifestation of multiple sclerosis.
Rehabilitation interventions in multiple sclerosis: an overview.
Cyclophosphamide as second-line therapy in multiple sclerosis: benefits and risks.
Discovery of fingolimod, the sphingosine 1-phosphate receptor modulator and its application for the therapy of multiple sclerosis.
Receptos, Inc. - Current Report: United States Securities and Exchange Commission Form 8-K

Pages